Breakthrough in aggressive breast cancer diagnostics JohnMay 30, 2017 3N Diagnostics (3NDx) has announced that its revolutionary Avisio FOXC1 immunohistochemistry (IHC) test for basal-like breast cancer (BLBC) has obtained CE Mark... Cutting EdgeInnovationMedTech
